Download PDF
CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2016; 74(11): 914-920
DOI: 10.1590/0004-282X20160129
CLINICAL SCALES, CRITERIA AND TOOLS

Brazilian-Portuguese translation, cross-cultural adaptation and validation of the Myasthenia Gravis Composite scale. A multicentric study

Tradução,adaptação cultural e validação da escala composta de Miastenia Grave para a lingua portuguesa do Brasil. Estudo multicêntrico
Ezequiel Fernandes Oliveira
1   Universidade Nove de Julho, Programa de Pós Graduação Mestrado e Doutorado em Ciências da Reabilitação, São Paulo SP, Brasil;
,
Valéria Cavalcante Lima
2   Universidade Federal de São Paulo, Departamento de Neurologia e Neurocirurgia, Divisão de Doença Neuromuscular, São Paulo SP, Brasill;
,
Eduardo Araujo Perez
3   Faculdade de Ciências Médicas da Santa Casa de São Paulo, Programa de Mestrado e Doutorado em Pesquisa em Cirurgia, São Paulo SP, Brasil;
,
Melissa Nunes Polaro
4   Faculdade de Ciências Médicas da Santa Casa de São Paulo, Departamento de Clínica Médica, Disciplina de Neurologia, São Paulo SP, Brasil;
,
Berenice Cataldo Oliveira Valério
4   Faculdade de Ciências Médicas da Santa Casa de São Paulo, Departamento de Clínica Médica, Disciplina de Neurologia, São Paulo SP, Brasil;
,
João R Pereiro
5   Hospital do Servidor Público Estadual, Programa de Pós Graduação em Ciências da Saúde, São Paulo SP, Brasil.
,
Sergio Roberto Nacif
5   Hospital do Servidor Público Estadual, Programa de Pós Graduação em Ciências da Saúde, São Paulo SP, Brasil.
,
Claudia Santos Oliveira
1   Universidade Nove de Julho, Programa de Pós Graduação Mestrado e Doutorado em Ciências da Reabilitação, São Paulo SP, Brasil;
,
Acary Souza Bulle Oliveira
2   Universidade Federal de São Paulo, Departamento de Neurologia e Neurocirurgia, Divisão de Doença Neuromuscular, São Paulo SP, Brasill;
,
Luis Vicente Franco Oliveira
1   Universidade Nove de Julho, Programa de Pós Graduação Mestrado e Doutorado em Ciências da Reabilitação, São Paulo SP, Brasil;
› Author AffiliationsSupport: LVFO received Research Productivity modality IB grants from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq; process no. 313053/2014-6) and, EFO receives grants from Fundaçao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP; protocol no. 2015/11738-6.
› Further Information
Also available at
   Permissions and Reprints

ABSTRACT

Objective To perform the translation, cultural adaptation and validation of the Myasthenia Gravis Composite (MGC) scale in Brazil.

Methods The study was conducted at three neuromuscular disease research centers in accordance with the international ethical standards, following a multi-modal approach and was conducted in three steps consisting of translation, cultural adaptation, and validation according to international guidelines. The final version of the MGC was applied in a sample of 27 MG patients and the total score was compared to a Portuguese version of the MG-QOL-15.

Results The internal consistency verified by Cohen’s Kappa test was excellent (0.766). The correlation between the MGC and MG-QOL-15 was strong (R = 0.777; p = 0.000). No significant differences were found between the responses of patients in the first and second applications of the MGC.

Conclusion The MGC scale, validated into Brazilian Portuguese, has proven to be a reliable instrument that is easy to use, and is highly reproducible.

RESUMO

Objetivo Realizar a tradução e a adaptação transcultural da escala composta de Miastenia Grave (ECMG) Myasthenia Gravis Composite (MGC) no Brasil.

Métodos O estudo foi realizado em três centros de investigação em doenças neuromusculares, de acordo com as normas éticas internacionais, consistindo em tradução, adaptação cultural e validação de acordo com as diretrizes internacionais. A versão final do MGC ECMG foi aplicada em vinte e sete pacientes com MG e a pontuação total foi comparada ao questionário MG-QOL 15.

Resultados A consistência interna verificada pelo teste Kappa de Cohen foi excelente (0,766) e a correlação entre o a ECMG MGC e MG-QOL 15 foi positiva (R = 0,777; p = 0,000). Não foram encontradas diferenças entre as respostas dos pacientes na primeira e segunda aplicação da MGC.

Conclusão A ECMG escala MGC validada para o Português do Brasil provou ser um instrumento confiável, de fácil aplicação e altamente reprodutível.

myasthenia gravis - translating - surveys and questionaires
miastenia gravis - tradução - inquéritos e questionários

Support:

LVFO received Research Productivity modality IB grants from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq; process no. 313053/2014-6) and, EFO receives grants from Fundaçao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP; protocol no. 2015/11738-6.




Publication History

Received: 16 March 2016

Accepted: 20 June 2016

Article published online:
06 September 2023

© 2023. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Drachman DB. Myasthenia gravis. N Engl J Med. 1994;330(25):1797-810.
  • 2 Patrick J, Lindstrom J. Autoimmune response to acetylcholine receptor. Science. 1973;180(4088):871-2. doi:10.1056/NEJM199406233302507
  • 3 Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurology. 2010;10(1):46. doi:10.1186/1471-2377-10-46
  • 4 Mao ZF, Mo XA, Qin C, Lai YR, Hartman TCO. Course and prognosis of myasthenia gravis: a systematic review. Eur J Neurol. 2010;17(7):913-21. doi:10.1111/j.1468-1331.2010.03017.x
  • 5 Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS et al. Myasthenia gravis: recommendations for clinical research standards. Ann Thorac Surg. 2000;70(1):327-34. doi:10.1016/S0003-4975(00)01595-2
  • 6 Cella DF, Tulsky DS. Measuring quality of life today: methodological aspects. Oncology (Willinston Park). 1990;4(5):29-38.
  • 7 Tindall RS, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med. 1987;316(12):719-24. doi:10.1056/NEJM198703193161205
  • 8 Tindall RS, Phillips JT, Rollins JA, Wells L, Hall K. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci. 1993;681 1 Myasthenia GR:539-51. doi:10.1111/j.1749-6632.1993.tb22937.x
  • 9 Tonali P, Padua L, Sanguinetti C, Padua R, Romanini E, Amadio P. Outcome research and patient-oriented measures in the multiperspective assessment of neurological and musculoskeletal disorders. Consensus Conference: Third Roman Neurophysiology Day, Outcome Research in Neurology and in Musculoskeletal Disorders – 24 October 1998. Ital J Neurol Sci. 1999;20(2):139-40. doi:10.1007/s100720050022
  • 10 Raggi A, Leonardi M, Antozzi C, Confalonieri P, Maggi L, Cornelio F et al. Concordance between severity of disease, disability and health-related quality of life in myasthenia gravis. Neurol Sci. 2010;31(1):41-5. doi:10.1007/s10072-009-0167-y
  • 11 Leonardi M, Raggi A, Antozzi C, Confalonieri P, Maggi L, Cornelio F et al. The relationship between health, disability and quality of life in myasthenia gravis: results from an Italian study. J Neurol. 2010;257(1):98-102. doi:10.1007/s00415-009-5279-z
  • 12 Morris J, Perez D, McNoe B. The use of quality of life data in clinical practice. Qual Life Res. 1998;7(1):85-91. doi:10.1023/A:1008893007068
  • 13 Padua L, Evoli A, Aprile I, Caliandro P, Batocchi AP, Punzi C et al. Myasthenia gravis outcome measure: development and validation of a disease-specific self-administered questionnaire. Neurol Sci. 2002;23(2):59-68. doi:10.1007/s100720200027
  • 14 Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology. 1999;22;52(7):1487. doi:10.1212/WNL.52.7.1487
  • 15 Muppidi S. The myasthenia gravis: specific activities of daily living profile. Ann N Y Acad Sci. 2012;1274(1):114-9. doi:10.1111/j.1749-6632.2012.06817.x
  • 16 Burns TM, Grouse CK, Conaway MR, Sanders DB. Construct and concurrent validation of the MG-QOL15 in the practice setting. Muscle Nerve. 2010;41(2):219-6. doi:10.1002/mus.21609
  • 17 Besinger UA, Toyka KV, Hömberg M, Heininger K, Hohlfeld R, Fateh-Moghadam A. Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology. 1983;33(10):1316-21. doi:10.1212/WNL.33.10.1316
  • 18 Burns TM, Conaway MR, Cutter GR, Sanders DB. Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite. Muscle Nerve. 2008;38(6):1553-62. doi:10.1002/mus.21185
  • 19 Mourão AM, Araújo CM, Barbosa LS, Gomez RS, Burns TM, Lemos SM et al. Brazilian cross-cultural translation and adaptation of the “Questionnaire of Life Quality Specific for Myasthenia Gravis - 15 items”. Arq. Neuropsiquiatr. 2013;71(12):955-58. doi:10.1590/0004-282X20130180
  • 20 Sadjadi R, Conaway M, Cutter G, Sanders DB, Burns TM. Psychometric evaluation of the myasthenia gravis composite using Rasch analysis. Muscle Nerve. 2012;45(6):820-5. doi:10.1002/mus.23260
  • 21 Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol. 1993;46(12):1417-32. doi:10.1016/0895-4356(93)90142-N
  • 22 Guillemin F. Cross-cultural adaptation and validation of health status measures. Scand J Rheumatol. 1995;24(2):61-3. doi:10.3109/03009749509099285
  • 23 Reichenheim ME, Moraes CL. Operationalizing the cross-cultural adaptation of epidemological measurement instruments. Rev Saúde Pública. 2007;41(4):665-73. doi:10.1590/S0034-89102006005000035
  • 24 Maher CG, Latimer J, Costa LOP. The relevance of cross-cultural adaptation and clinimetrics for physical therapy instruments. Rev Bras Fisioter. 2007;11(4):245-52. doi:10.1590/S1413-35552007000400002
  • 25 Beaton D, Bombardier C, Guillemin F, Ferraz MB. Guidelines for process of cross-cultural adaptation of self-report measures. Spine. 2000;(25)24:3186-91. doi:10.1097/00007632-200012150-00014
  • 26 Oliveira EF, Urbano JJ, Santos IR, Silva AS, Guimarães LL, Peixoto RAO et al. Brazilian translation, cross-cultural adaptation and validation of the MG Composite scale and Quantitative Myasthenia gravis testing form: a multicentric study protocol. Man Ther Posturology Rehabil J. 2016;14:1-5. doi:10.17784/mtprehabjournal.2016.14.342
  • 27 Benatar M, Sanders DB, Burns TM, Cutter GR, Guptill JT, Baggi F et al. Recommendations for myasthenia gravis clinical trials. Muscle Nerve. 2012;45(6):909-17. doi:10.1002/mus.23330
  • 28 Burns TM, Conaway M, Sanders DB, MG Composite and MG-QOL15 Study Group. The MG Composite. A valid and reliable outcome measure for myasthenia gravis. Neurology. 2010;74(18):1434-40. doi:10.1212/WNL.0b013e3181dc1b1e
  • 29 Burns TM. The MG composite: an outcome measure for myasthenia gravis for use in clinical trials and everyday practice. Ann N Y Acad Sci. 2012;1274(1):99-106. doi:10.1111/j.1749-6632.2012.06812.x
  • 30 Morris J, Perez D, McNoe B. The use of quality of life data in clinical practice. Qual Life Res;1998;7(1):85-91. doi:10.1023/A:1008893007068